Utility of a Fifth-Generation Ultrasensitive Prostate-Specific Antigen Assay for Monitoring Prostate Cancer Patients after Radical Prostatectomy with 3 Years of Follow-Up.

CONCLUSIONS: The uPSA MesoScale technology could track miniscule changes in serum PSA in the range of 0.003-1 pg/mL in all RP cases. However, PSA kinetics and nadir at concentrations <2 pg/mL fluctuated, and increases below this range could not reliably suggest signs of BCR. Instead, ultrasensitive fifth-generation PSA assays may hold clinical potential for measuring the low concentrations of PSA in women for various medical contexts.
PMID: 33001184 [PubMed - as supplied by publisher]

Source: Clinical Prostate Cancer - September 30, 2020 Category: Cancer & Oncology Authors: Ren AH, Soosaipillai A, Mathew A, Nikolenko G, Sardesai L, Stengelin M, Diamandis EP Tags: Clin Chem Source Type: research